Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

Clinical Microbiology and Infection

Volumn 18, Issue 8, 2012, Pages

  Colafigli, M ^a   Torti, C ^b   Trecarichi, E M ^a   Albini, L ^b   Rosi, A ^c   Micheli, V ^d   Manca, N ^b   Penco, G ^e   Bruzzone, B ^f   Punzi, G ^g   Corsi, P ^h   Parruti, G ⁱ   Bagnarelli, P ^j   Monno, L ^g   Gonnelli, A ^k   Cauda, R ^a   Di Giambenedetto, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ Hospital of Pescara   (Italy)

^j UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^k UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

Antiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

DISEASE TRANSMISSION; FEMALE; GENE MUTATION; GENOTYPE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; ITALY; MAJOR CLINICAL STUDY; MALE; NOTE; PREDICTOR VARIABLE; PRIORITY JOURNAL; TRANSMITTED DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864047302     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03847.x     Document Type: Article

References (11)

1. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106.
2. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011;154:445-456. Epub 2011 Feb 14
3. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
4. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
5. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786
6. Riva C, Lai A, Caramma I. Transmitted HIV Type 1 drug resistance and Non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy. AIDS Res Hum Retroviruses 2010; 26: 41-49.
7. Alteri C, Svicher V, Gori C et al. Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs. BMC Infect Dis 2009; 9: 111.
8. Bracciale L, Colafigli M, Zazzi M et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. JAC 2009; 64: 607-615.
9. Bennet DE, Camacho R, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.
10. Torti C, Lapadula G, Izzo I et al. Heterogeneity and penetration of HIV-1 non-subtypes B virus in an Italian province: public health implications. Epidemiol Infect 2010; 138: 1298-1307.
11. Harrison L, Castro H, Cane P et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 2010; 24: 1917-1922.